How Biotech Startups Use Gene Switches to Control Protein Production

In episode 41, Lucas and Luna explore the emerging field of synthetic gene switches — biological circuits that allow biotech startups to precisely control when and where therapeutic proteins are made inside a patient's body. The conversation centers on a real startup called Senti Biosciences, which has engineered logic-gated gene circuits that can distinguish between healthy and diseased cells. Lucas explains how a company can use a synthetic 'kill switch' to turn off a therapy if dangerous side effects emerge, and how inducible promoters respond to small molecules like doxycycline to toggle gene expression on and off. The episode also touches on the promise of cell-based therapies and the regulatory challenges facing these programmable biologics. #GeneSwitches #SyntheticBiology #SentiBiosciences #CellTherapy #GeneTherapy #ProteinProduction #InduciblePromoters #KillSwitch #LogicGates #BiotechStartups #DrugDevelopment #Biologics #LifeSciences #BusinessAndTechnology #Podcast #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo